20 December 2016

A new study published in Nature Communications elucidates how the cancer vaccine adjuvant saponin potentiates antigen cross-presentation in dendritic cells through induction of lipid bodies.

Cancer vaccines

Martijn den Brok (photo up) and colleagues in the lab of Gosse Adema. theme Cancer development and immune defense, together with colleagues from amongst others MSD (former Intervet) strive to develop and advance cancer vaccines. Vaccine improvement for the treatment of established cancer has proven challenging. Saponin-based adjuvants are gaining ground as component in animal and human (cancer) vaccines, since they induce protective cellular immunity. Their adjuvant potency has been related to enhanced antigen cross-presentation by dendritic cells (DCs) that is crucial for cellular immunity. How these adjuvants act to induce antigen cross-presentation by DCs has remained obscure.

A team of researchers led by Gosse Adema from the Dept. of Tumor Immunology now shows that saponin adjuvant exposure enhances antigen cross-presentation through the induction of intracellular Lipid Bodies in a specific monocytic DC subset. Lipid body organelles consist of a phospholipid monolayer containing numerous unknown proteins that surrounds a core of neutral lipids, such as sterol esters or triacylglycerols. Using genetic and pharmacological interference in models for vaccination and in situ tumor-ablation, the authors demonstrate that lipid body induction is causally related to the saponin-dependent increase in cross-presentation and T-cell activation. 

These novel findings aid the application of saponin-based adjuvants as cancer vaccine component, and will stimulate development of new adjuvants enforcing T-cell-mediated immunity.

Publication

Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.

 

Related news items


Ignacio Malagon, first professor of Pediatric Anaesthesiology in the Netherlands

21 January 2019

Ignacio Malagon has been appointed professor of Pediatric Anaesthesiology at Radboud University / Radboud university medical center with effect from 1 January 2019. He is the first professor in this field in the Netherlands.

read more

Thomas Maal appointed full professor of 3D Technology in Healthcare

7 January 2019

3D technology leads to better care and lower costs.

read more

Quickly detecting actual heart attacks prevents unnecessary hospital visits Research by Radboud university medical center improves efficacy and reduces cost of cardiac care

4 January 2019

Many patients who suffer from chest pain are not actually having a heart attack, making an emergency hospital visit unnecessary. Is there a way to quickly and accurately determine at home whether emergency hospital treatment is necessary?

read more

Radboud university medical center treats metastatic liver cancer with holmium microspheres MRI imaging during surgery can improve the outcome

4 January 2019

For the first time Radboud university medical center has treated a patient with liver metastases by using holmium radio-embolization. With this technique, radioactive holmium microspheres are injected via a catheter into the liver artery.

read more

Research into drugs for treating rare diseases can be more efficient and patient-oriented

18 December 2018

To assess whether a drug is an effective treatment for a rare disease, large-scale research with Randomized Controlled Trials may not be necessary in all situations, say researchers from the departments of Neurology and Health Evidence in the Journal of the American Medical Association (JAMA).

read more